Dyslipidaemia in 2015: Advances in treatment of dyslipidaemia

Nature Reviews Cardiology

Volumn 13, Issue 2, 2016, Pages 74-75

  Grundy, Scott M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALIROCUMAB; CHOLESTEROL; EVOLOCUMAB; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; SERINE PROTEINASE INHIBITOR; SIMVASTATIN; AZETIDINE DERIVATIVE; BIOLOGICAL MARKER; EZETIMIBE GLUCURONIDE; GLUCURONIDE; HYPOCHOLESTEROLEMIC AGENT; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

ACUTE CORONARY SYNDROME; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY ATHEROSCLEROSIS; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; META ANALYSIS (TOPIC); MORTALITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG EFFECTS; DYSLIPIDEMIAS; HYPERLIPOPROTEINEMIA TYPE II; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; BIOMARKERS; CHOLESTEROL, LDL; DYSLIPIDEMIAS; GLUCURONIDES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; META-ANALYSIS AS TOPIC; PROPROTEIN CONVERTASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SERINE ENDOPEPTIDASES; TREATMENT OUTCOME;

EID: 84955373575     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2015.208     Document Type: Review

References (5)

1. Cholesterol Treatment Trialists (CTT) Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-Analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 385, 1397-1405 (2015).
2. Cannon, C. P., et al. Ezetimibe added to statin therapy after acute coronary syndromes. N. Engl. J. Med. 372, 2387-2397 (2015).
3. Jarcho, J. A. & Keaney, J. F. Jr. Proof that lower is better-LDL cholesterol and IMPROVE IT. N. Engl. J. Med. 372, 2448-2450 (2015).
4. Robinson, J. G., et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 372, 1489-1499 (2015).
5. Sabatine, M. S., et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 372, 1500-1509 (2015).